VCX3B
gene geneOn this page
Also known as VCX-C
Summary
VCX3B (variable charge X-linked 3B, HGNC:31838) is a protein-coding gene on chromosome Xp22.31, encoding Variable charge X-linked protein 3B (Q9H321). May mediate a process in spermatogenesis or may play a role in sex ratio distortion.
This gene belongs to the VCX/Y gene family, which has multiple members on both X and Y chromosomes, and all are expressed exclusively in male germ cells. The X-linked members are clustered on chromosome Xp22, and the Y-linked members are two identical copies of the gene within a palindromic region on chromosome Yq11. The family members share a high degree of sequence identity, with the exception that a 30-nt unit is tandemly repeated in X-linked members but occurs only once in Y-linked members. The VCX gene cluster is polymorphic in terms of copy number; different individuals may have a different number of VCX genes. This family member, as represented by the reference genome allele, contains 14 copies of the 30-nt repeat unit. VCX/Y genes encode small and highly charged proteins containing putative bipartite nuclear localization signals. Although the exact function of this family member has yet to be determined, a role in mRNA stability regulation can be inferred from the ability of the highly similar family member, VCX-A, to inhibit mRNA decapping. A possible role in the regulation of ribosome assembly during spermatogenesis has also been suggested.
Source: NCBI Gene 425054 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 130 total
- MANE Select transcript:
NM_001001888
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:31838 |
| Approved symbol | VCX3B |
| Name | variable charge X-linked 3B |
| Location | Xp22.31 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | VCX-C |
| Ensembl gene | ENSG00000205642 |
| Ensembl biotype | protein_coding |
| OMIM | 300981 |
| Entrez | 425054 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000381032
RefSeq mRNA: 1 — MANE Select: NM_001001888
NM_001001888
CCDS: CCDS48077
Canonical transcript exons
ENST00000381032 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001487283 | 8465745 | 8466510 |
| ENSE00001667677 | 8465305 | 8465552 |
| ENSE00001786778 | 8464830 | 8464990 |
Expression profiles
Bgee: expression breadth broad, 100 present calls, max score 89.05.
Top tissues by expression
122 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right testis | UBERON:0004534 | 89.05 | gold quality |
| left testis | UBERON:0004533 | 88.04 | gold quality |
| testis | UBERON:0000473 | 87.17 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 85.35 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 83.55 | gold quality |
| apex of heart | UBERON:0002098 | 55.38 | gold quality |
| metanephros cortex | UBERON:0010533 | 55.04 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 52.75 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 51.76 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 47.77 | gold quality |
| thyroid gland | UBERON:0002046 | 47.30 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 47.17 | gold quality |
| hypothalamus | UBERON:0001898 | 45.96 | gold quality |
| cortex of kidney | UBERON:0001225 | 45.80 | gold quality |
| right atrium auricular region | UBERON:0006631 | 45.69 | gold quality |
| putamen | UBERON:0001874 | 45.61 | gold quality |
| heart left ventricle | UBERON:0002084 | 45.51 | gold quality |
| primary visual cortex | UBERON:0002436 | 45.18 | gold quality |
| right uterine tube | UBERON:0001302 | 44.61 | silver quality |
| anterior cingulate cortex | UBERON:0009835 | 44.39 | gold quality |
| amygdala | UBERON:0001876 | 44.06 | gold quality |
| right adrenal gland | UBERON:0001233 | 43.99 | gold quality |
| right coronary artery | UBERON:0001625 | 43.92 | gold quality |
| temporal lobe | UBERON:0001871 | 43.86 | gold quality |
| caudate nucleus | UBERON:0001873 | 43.52 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 43.12 | gold quality |
| adenohypophysis | UBERON:0002196 | 43.08 | gold quality |
| heart | UBERON:0000948 | 43.07 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 42.80 | gold quality |
| nucleus accumbens | UBERON:0001882 | 42.73 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-134144 | yes | 2775.31 |
| E-GEOD-124263 | yes | 1231.55 |
| E-ANND-3 | no | 0.32 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
2 targeting VCX3B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-2861 | 95.24 | 65.47 | 1056 |
| HSA-MIR-3615 | 95.04 | 65.37 | 109 |
Cross-species orthologs
0 orthologs
Paralogs (5): VCY1B (ENSG00000129862), VCY (ENSG00000129864), VCX3A (ENSG00000169059), VCX2 (ENSG00000177504), VCX (ENSG00000182583)
Protein
Protein identifiers
Variable charge X-linked protein 3B — Q9H321 (reviewed: Q9H321)
Alternative names: Variably charged protein X-C
All UniProt accessions (1): Q9H321
UniProt curated annotations — full annotation on UniProt →
Function. May mediate a process in spermatogenesis or may play a role in sex ratio distortion.
Tissue specificity. Expressed exclusively in testis.
Similarity. Belongs to the VCX/VCY family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9H321-1 | 1 | yes |
| Q9H321-2 | 2 |
RefSeq proteins (1): NP_001001888* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR026653 | VCX/VCY1 | Family |
Pfam: PF15231
UniProt features (32 total): repeat 14, compositionally biased region 10, sequence conflict 3, region of interest 2, chain 1, splice variant 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9H321-F1 | 46.84 | 0.00 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 6 (showing top):
GOBP_HEAD_DEVELOPMENT, GOCC_NUCLEOLUS, chrXp22, PAX3_TARGET_GENES, FOURATI_BLOOD_TWINRIX_AGE_25_83YO_RESPONDERS_VS_POOR_RESPONDERS_0DY_DN, GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT
GO Biological Process (1): brain development (GO:0007420)
GO Molecular Function (0):
GO Cellular Component (2): nucleus (GO:0005634), nucleolus (GO:0005730)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| central nervous system development | 1 |
| animal organ development | 1 |
| head development | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| intracellular membraneless organelle | 1 |
Protein interactions and networks
STRING
582 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| VCX3B | ARX | Q96QS3 | 670 |
| VCX3B | PUDP | Q08623 | 600 |
| VCX3B | PNPLA4 | P41247 | 580 |
| VCX3B | STS | P08842 | 516 |
| VCX3B | DCP2 | Q8IU60 | 477 |
| VCX3B | ARSF | P54793 | 476 |
| VCX3B | HSFX1 | Q9UBD0 | 452 |
| VCX3B | TGIF2LX | Q8IUE1 | 448 |
| VCX3B | FAM47C | Q5HY64 | 402 |
| VCX3B | XAGE5 | Q8WWM1 | 391 |
| VCX3B | NLGN4X | Q8N0W4 | 388 |
| VCX3B | CPXCR1 | Q8N123 | 370 |
| VCX3B | CYLC1 | P35663 | 370 |
| VCX3B | ANOS1 | P23352 | 369 |
| VCX3B | DYDC1 | Q8WWB3 | 366 |
IntAct
0 interactions, top by confidence:
ESM2 similar proteins: A0A087WUL8, A0A0J9YWL9, A0A0U1RQI7, A0A1D9BZF0, A6NJU9, A6NKU9, A6NNC1, A6QL64, A8MRT5, B2SU53, B4DH59, B5DUH6, C9JG80, E5RHQ5, F8W0I5, P01068, P02895, P06916, P07907, P0DKL2, P0DPF3, P0DRJ4, P13208, P14417, P32072, P83060, Q26755, Q3BBV0, Q3BBV2, Q4ZJY7, Q4ZJZ0, Q4ZJZ1, Q4ZJZ3, Q5TAG4, Q5TI25, Q6P3W6, Q6RY98, Q7T3L1, Q86SG3, Q86T75
Diamond homologs: O14598, Q9H320, Q9H321, Q9H322, Q9NNX9
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
130 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 96 |
| Likely benign | 27 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
231 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| X:8465370:T:TA | acceptor_gain | 0.9300 |
| X:8464905:GT:G | donor_gain | 0.9100 |
| X:8465371:G:A | acceptor_gain | 0.9000 |
| X:8465549:GAAG:G | donor_gain | 0.8700 |
| X:8465551:AGG:A | donor_loss | 0.8600 |
| X:8465552:GGT:G | donor_loss | 0.8600 |
| X:8465553:G:GG | donor_gain | 0.8600 |
| X:8464932:G:T | donor_gain | 0.8500 |
| X:8465742:CAG:C | acceptor_loss | 0.8500 |
| X:8465743:A:AG | acceptor_gain | 0.8500 |
| X:8465743:AG:A | acceptor_loss | 0.8500 |
| X:8465744:G:GC | acceptor_loss | 0.8500 |
| X:8465744:G:GG | acceptor_gain | 0.8500 |
| X:8465554:T:A | donor_loss | 0.8400 |
| X:8465731:T:TA | acceptor_gain | 0.8300 |
| X:8465734:T:A | acceptor_gain | 0.8200 |
| X:8465744:GA:G | acceptor_gain | 0.8200 |
| X:8465744:GACT:G | acceptor_gain | 0.8100 |
| X:8465200:G:C | acceptor_gain | 0.8000 |
| X:8465510:G:GT | donor_gain | 0.8000 |
| X:8465742:CAGA:C | acceptor_gain | 0.8000 |
| X:8464884:G:GT | donor_gain | 0.7900 |
| X:8465551:AG:A | donor_gain | 0.7900 |
| X:8465552:GG:G | donor_gain | 0.7900 |
| X:8465378:CGAG:C | acceptor_gain | 0.7800 |
| X:8465550:AAG:A | donor_gain | 0.7800 |
| X:8465741:CCAGA:C | acceptor_gain | 0.7800 |
| X:8465744:GACTA:G | acceptor_gain | 0.7700 |
| X:8465744:GAC:G | acceptor_gain | 0.7600 |
| X:8465548:AGAAG:A | donor_gain | 0.7500 |
AlphaMissense
1642 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| X:8466135:A:C | S165R | 0.924 |
| X:8466137:T:A | S165R | 0.924 |
| X:8466137:T:G | S165R | 0.924 |
| X:8466165:A:C | S175R | 0.920 |
| X:8466167:T:A | S175R | 0.920 |
| X:8466167:T:G | S175R | 0.920 |
| X:8466105:A:C | S155R | 0.915 |
| X:8466107:T:A | S155R | 0.915 |
| X:8466107:T:G | S155R | 0.915 |
| X:8466195:A:C | S185R | 0.913 |
| X:8466197:T:A | S185R | 0.913 |
| X:8466197:T:G | S185R | 0.913 |
| X:8466225:A:C | S195R | 0.906 |
| X:8466227:T:A | S195R | 0.906 |
| X:8466227:T:G | S195R | 0.906 |
| X:8466255:A:C | S205R | 0.892 |
| X:8466257:T:A | S205R | 0.892 |
| X:8466257:T:G | S205R | 0.892 |
| X:8466075:A:C | S145R | 0.887 |
| X:8466077:T:A | S145R | 0.887 |
| X:8466077:T:G | S145R | 0.887 |
| X:8466174:A:C | S178R | 0.880 |
| X:8466176:C:A | S178R | 0.880 |
| X:8466176:C:G | S178R | 0.880 |
| X:8466045:A:C | S135R | 0.876 |
| X:8466047:T:A | S135R | 0.876 |
| X:8466047:T:G | S135R | 0.876 |
| X:8466144:A:C | S168R | 0.871 |
| X:8466146:C:A | S168R | 0.871 |
| X:8466146:C:G | S168R | 0.871 |
dbSNP variants (sampled 300 via entrez): RS1003055612 (X:8464536 A>G), RS1006713455 (X:8464651 A>C,G), RS1010434601 (X:8463365 T>C), RS1010490710 (X:8464026 T>C), RS1016659249 (X:8464293 TTG>T), RS1020395042 (X:8462882 A>G), RS1020447338 (X:8463370 G>A,C), RS1020499716 (X:8464063 A>C,G), RS1030221104 (X:8464743 G>A), RS1034400450 (X:8463469 C>T), RS1034451205 (X:8464241 A>G), RS1036125300 (X:8463052 G>A,C), RS1041995679 (X:8464508 T>C), RS1046068525 (X:8465233 C>CA,CG), RS1050089064 (X:8463081 G>A)
Disease associations
OMIM: gene MIM:300981 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000477_16 | Cognitive performance | 8.000000e-06 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0003926 | neuropsychological test |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
4 total (human), top 4 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Acetaminophen | decreases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Thapsigargin | increases expression | 1 |
| Copper Sulfate | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.